#Germany #London #IOL #Cataract #ZEISS AT LUCIA

ZEISS Launches Groundbreaking IOL for Cataract Patients

ZEISS Medical Technology recently announced the commercial availability of the ZEISS AT LUCIA toric 721P, which represents a milestone in intraocular lens (IOL) technology. Officially unveiled at the European Society of Cataract and Refractive Surgeons (ESCRS) congress held in London from September 11 to 14, this device is notable for being the world's first hydrophobic monofocal IOL featuring a bitoric optic, paired with a novel asphericity design. This state-of-the-art lens has the potential to revolutionize how cataracts and astigmatism are treated simultaneously.

With the introduction of the AT LUCIA toric 721P, ZEISS expands its already impressive LUCIA Family, which is recognized for treating cataracts without compromising on astigmatism correction. The unique non-constant asphericity profile design enables the lens to perform consistently across different ocular conditions by adjusting for variations in pupil size, corneal spherical aberration, and natural lens position. This approach is particularly crucial for ensuring high patient satisfaction in real-world scenarios, as it caters to the diversity found in patients’ eye characteristics.

Features and Benefits

ZEISS is known for its cutting-edge optical solutions, and the AT LUCIA toric 721P certainly upholds that reputation. Andreas Völker, Head of the Ophthalmology Strategic Business Unit, noted, "This launch is a testament to ZEISS's commitment to advancing optical technology, giving surgeons worldwide more options and empowering them to achieve better outcomes for their patients."

Moreover, Frank Seitzinger, Head of the Business Sector Surgery Anterior Segment, referred to this lens as a “game changer” for those managing astigmatism. Its reliability and lens platform stability are expected to substantially improve workflows for surgeons, making astigmatism management more effective and streamlined.

Celebrating Innovation at ESCRS

During the ESCRS event, ZEISS planned to host a special celebration on September 12 at their booth in the South Event Hall. This would feature presentations from surgeons who participated in early clinical evaluations of the lens, sharing their firsthand insights and experiences. High-profile attendees included surgeons from various prestigious institutions, such as Prof. Gerd Auffarth from the Heidelberg University Hospital and Dr. Amin Kassem from Värnamo Ögoncenter in Sweden. A highlight of the event was the presentation of the “ZEISS AT LUCIA toric Pioneer Award” to early adopters who have been instrumental in utilizing this innovative technology in their practices.

Availability and Market Reach

The ZEISS AT LUCIA toric 721P is already CE marked and is now available in select European countries, including Germany, Italy, Spain, Portugal, and France. As with all medical technologies, it is crucial to keep in mind that product availability may vary by region, and approvals might differ depending on local regulations.

In summary, the launch of the AT LUCIA toric 721P marks a significant advancement in intraocular lens technology, aligning with ZEISS's long-standing mission to enhance patient care through innovative solutions. With an emphasis on reliability and effectiveness, this product is set to redefine standards in cataract and astigmatism management, supporting surgeons in providing improved outcomes for their patients. For further information, interested parties can explore the details on ZEISS’s dedicated website.